Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06657768 · ClinicalTrials.gov registry record · Phase 1

A Study of LY4006895 in Healthy Participants With Early Symptomatic Alzheimer's Disease (AD)

A Phase 1 study of Healthy and Alzheimer Disease, sponsored by Eli Lilly and Company.

Recruiting
Registry status
Phase 1
Development phase
128
Enrollment target
9
Study locations

NCT06657768 is a Phase 1 study of Healthy and Alzheimer Disease that is actively recruiting participants, run by Eli Lilly and Company. The registered enrollment target is 128 participants, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (80% lower). The trial reports 9 study locations across 6 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06657768, a Phase 1 study of Healthy and Alzheimer Disease, is actively recruiting participants, sponsored by Eli Lilly and Company.

RECRUITING
Registry status
Phase 1
Development phase
128 participants
Enrollment target
9
Study locations

Study Summary

The main purpose of this study is to evaluate the safety and tolerability of the study drug known as LY4006895. Part A will administer a single-ascending dose in healthy participants or Part B will administer multiple-ascending doses in participants with early symptomatic Alzheimer's Disease (AD). Blood tests will be performed to check how much LY4006895 gets into the bloodstream and how long it takes the body to eliminate it. This is a 2-part study and will last approximately 29 weeks for Part A and 61 weeks for Part B, including a screening period for each part.

Conditions Studied

Healthy Alzheimer Disease

Interventions

  • DRUG Placebo
  • DRUG LY4006895

Study Locations (9)

Florida

  • K2 Medical Research - The Villages - Lady Lake
  • K2 Medical Research - Maitland

Georgia

  • Atlanta Center of Medical Research - Atlanta
  • CenExel iResearch, LLC (CenExel iRA) - Decatur

Other

  • The University of Tokyo Hospital - Bunkyō City
  • National Center for Geriatrics and Gerontology - Ōbu

California

  • Collaborative Neuroscience Network - CNS - Los Alamitos

New Jersey

  • CenExel-HRI - Marlton

North Carolina

  • Duke Early Phase Research Unit - Durham

Trial Details

FieldValue
Enrollment Target 128 participants
Start Date 2024-10-29
Est. Completion 2027-07
Phase Phase 1

Sponsor

Eli Lilly and Company

1,341 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06657768

The ClinicalTrials.gov registry entry for NCT06657768 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 128 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (80% lower). The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Healthy appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT06657768 reports 9 study locations spanning 6 distinct geographic areas - top geographies include Florida, Georgia, Other.

Frequently Asked Questions

What is clinical trial NCT06657768 about?

NCT06657768 is a clinical study titled "A Study of LY4006895 in Healthy Participants With Early Symptomatic Alzheimer's Disease (AD)". The main purpose of this study is to evaluate the safety and tolerability of the study drug known as LY4006895. Part A will administer a single-ascending dose in healthy participants or Part B will administer multiple-ascending doses in participants with early symptomatic Alzheimer's Disease (AD). ...

What is the current status of trial NCT06657768?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 128 participants. The study started on 2024-10-29. Estimated completion is 2027-07.

What conditions does trial NCT06657768 study?

This clinical trial studies the following conditions: Healthy, Alzheimer Disease.

What interventions are being tested in trial NCT06657768?

The interventions under investigation include: Placebo (DRUG), LY4006895 (DRUG).

Who is sponsoring clinical trial NCT06657768?

This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06657768 being conducted?

This trial has 9 study locations across California, Florida, Georgia, New Jersey, North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Healthy

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Healthy

All registered trials for this condition

Alzheimer Disease

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.